Weight loss drugs increase the risk of hair loss - study
Kyiv • UNN
A study of 50,000 people found a link between GLP-1 agonists and alopecia. Regulators in the US and UK have received hundreds of reports of hair loss.
Researchers have found a link between the use of weight loss drugs based on GLP-1 agonists and an increased risk of hair loss. The findings are based on a study involving about 50,000 people. This was reported by Sky News, UNN reports.
Details
According to the publication, in a new study involving about 50,000 people, experts compared hair loss rates in alopecia among adults who used GLP-1 agonists to treat diabetes with those who took other medications. Researchers claim that weight loss drugs such as Mounjaro, Ozempic, and Wegovy are associated with an increased risk of hair loss.
People taking GLP-1 agonist drugs, which help regulate blood sugar levels and reduce appetite by mimicking a natural hormone, have reported hair loss to regulatory bodies, and a new study involving about 50,000 people confirms this link
A team from the University of Pennsylvania reported that regulatory authorities in the United States have been informed about the link between the drugs and hair loss, particularly for semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro).
As of 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has received about 400 reports of hair loss associated with tirzepatide, compared to 541 reports last year. It also received 148 reports of hair loss associated with semaglutide, compared to 164 reports last year
Recall
Scientists have created a new cermet material characterized by lightness, strength, and high damping.